# Role of Nutribiotics in Skin Care
## 5 Nutribiotics: An Opportunity to Improve Skin Health
\begin{table}
\begin{tabular}{c c c} \hline \hline
**Skin Disease or Condition** & **Pre/Pro/Synbiotics** & **Key Results \({}^{*}\)** & **Reference** \\ \hline _Lactobacillus acidophilus_ and & 80\% clinical improvement & [PERSON] 1961 [140] \\ _Lactobacillus bugierics_ & & \\ \hline _L. acidophilus_ and _Bifidobacterium_ & Adjuvant in antibiotic therapy & [PERSON] et al., 1987 [141] \\ _bifidatum_ & & \\ \hline _Lactobacillus acidophilus_, & 67\% reduction in lesion counts & \\ _Lactobacillus delbrueckii bulgarixics_, & after twelve weeks & [PERSON] et al., 2013 [133] \\ and _B. bifidatum_ & & \\ \hline _Lactobacillus rhamnosus_ SP1 & 32\% reduction in IGF-1 and a 65\% & [PERSON] et al., 2016 [142] \\  & & increase in FOXOOI & \\ \hline _B. lactis VS1, B. lactis WS2,_ & & \\ _L. acidophilus WS5, L. casi w56,_ & Increase in IL-10 levels & [PERSON] et al., 2019 [143] \\ _L. salivarius WS5, L. lactis WS8_ & & Inhibition of CD-4+ T cell \\ Acne & _Lactobacillus paracasi_ NCC2461 & activation and induction of the anti-inflammatory cytokines IL-10 & [PERSON] et al., 2014 [144] \\  & & and TGF-b. & \\ \hline _Konjac glucomanan_ & & \\ _hydrolasesates + (L. casi,_ & & \\ _L. plantatum, L. gesseri, L. lactis)_ & Inhibition of bacteria growth & [PERSON] et al., 2010 [145] \\ \hline _Escherichia coli_ Nissle 1917 & 80\% clinical improvement & [PERSON] et al., 2016 [146] \\ \hline _Bifidobacterium brere_ BR03 DSM & & \\ 16604, _Lacticisobacillus casi_ LC03 DSM 27537, and _Ligilatobacillus salivarius_ LS03 DSM 22776 + & Decrease in the number of acne & \\ _Solanum melongena_ and _Echinacea_ & lesions, rate of desquamation, rate & [PERSON] et al., 2022 [147] \\ botanical extract & & of _C. acnes_ & \\ \hline _Nitrosomonas eutropha_ & Significant reduction in overall & \\  & & severity & AOBiome [148] \\  & & Reduction in the number of & \\  & inflammatory lesions & \\ \hline _Oligosaccharide_ & Lower 5-year cumulative & \\ _prebiotic-supplemented formula_ & incidence of AD & [PERSON] et al., 2012 [149] \\ \hline _Mivature of neutral_ & & \\ _oligosaccharides and_ & Primary prevention of AD in & \\ _pectin-derived acidic_ & low-atopy-risk infants & [PERSON] et al., 2010 [150] \\ _oligosaccharides_ & & \\ \hline _Lactobacillus rhamnosus_ GG & Improvement in SCORAD & \\ _Lactobacillus rhamnosus_ GG & Decrease in TNF-\(\alpha\) and fecal & [PERSON] et al., 2000 [151] \\  & & \(\alpha\)1-antitrypsin & \\ \hline _Atopic dermatitis_ & Anti-inflammatory activity & \\ _Lactobacillus rhamnosus_ GG & Increased levels of IL-10 and (TGF-\(\beta\)2) & [PERSON] et al., 2000; [PERSON] et al., 2002 [152,153] \\ \hline _Lactobacillus rhamnosus_ 19070-2 & Moderate improvement in clinical & \\ _and Lactobacillus reuteri_ & Severity & [PERSON] et al., 2003 [154] \\ _DSM 12246_ & Decreased proportions of IgA- & [PERSON] et al., 2011 [155] \\ \hline _Lactobacillus rhamnosus_ GG & Decrease proportions of IgA- & \\ _and IgM-secreting cells_ & [PERSON] et al., 2011 [155] \\ \hline _Bifidobacterium lactis_ HN019 and & Improvement in natural killer cell & \\ _Lactobacillus rhamnosus_ HN001 & and phagocytic activity & \\ \hline \hline \end{tabular}
\end{table} 
Table 2: Oral pre-, pro-, syn-, post-, and para-probiotics used in skin care (clinical studies).